Kwality Pharmaceuticals Intrinsic Value
KPL Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1196.80 | ₹957.44 - ₹1436.16 | +9.6% | EPS: ₹54.40, Sector P/E: 22x |
| Book Value Method | asset | ₹524.00 | ₹471.60 - ₹576.40 | -52.0% | Book Value/Share: ₹262.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹896.00 | ₹806.40 - ₹985.60 | -18.0% | Revenue/Share: ₹448.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1037.90 | ₹934.11 - ₹1141.69 | -5.0% | EBITDA: ₹104.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹719.92 | ₹575.94 - ₹863.90 | -34.1% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹348.16 | ₹313.34 - ₹382.98 | -68.1% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹840.48 | ₹756.43 - ₹924.53 | -23.1% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹896.00 | ₹806.40 - ₹985.60 | -18.0% | ROE: 21.4%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹524.00 | ₹471.60 - ₹576.40 | -52.0% | EPS: ₹54.40, BVPS: ₹262.00 |
Want to compare with current market value? Check KPL share price latest .
Valuation Comparison Chart
KPL Intrinsic Value Analysis
What is the intrinsic value of KPL?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Kwality Pharmaceuticals (KPL) is ₹840.48 (median value). With the current market price of ₹1092.35, this represents a -23.1% variance from our estimated fair value.
The valuation range spans from ₹348.16 to ₹1196.80, indicating ₹348.16 - ₹1196.80.
Is KPL undervalued or overvalued?
Based on our multi-method analysis, Kwality Pharmaceuticals (KPL) appears to be trading above calculated value by approximately 23.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 18.93 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.71 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 21.4% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 23.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.00x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Kwality Pharmaceuticals
Additional stock information and data for KPL
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹53 Cr | ₹39 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹43 Cr | ₹30 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹41 Cr | ₹17 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹61 Cr | ₹30 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹27 Cr | ₹16 Cr | Positive Free Cash Flow | 8/10 |